Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms
- PMID: 1993898
- DOI: 10.1111/j.1471-4159.1991.tb02009.x
Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms
Abstract
The effects of various cholecystokinin (CCK)-related peptides were investigated on 35 mM K(+)-stimulated endogenous dopamine release from slices of either anterior or posterior nucleus accumbens of the rat. CCK sulphated octapeptide (1-10 microM), but not pentagastrin or CCK unsulphated octapeptide, was found to cause a dose-dependent increase in the release from the posterior nucleus accumbens. This effect was blocked by low doses of the CCKA receptor antagonist L364,718 (10 nM) but not the CCKB receptor antagonist L365,260. In the anterior nucleus accumbens CCK sulphated octapeptide (1 microM) and CCK unsulphated octapeptide (0.1-1 microM) inhibited the dopamine release, and this effect was blocked by L365,260 (10-100 nM) but not by L364,718. These results suggest that CCK has a different effect on dopamine release from the anterior and posterior nucleus accumbens and that these effects are mediated by two different types of CCK receptor.
Similar articles
-
Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.Br J Pharmacol. 1990 Apr;99(4):845-8. doi: 10.1111/j.1476-5381.1990.tb13018.x. Br J Pharmacol. 1990. PMID: 2361176 Free PMC article.
-
Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites.J Neurochem. 1997 Jan;68(1):162-8. doi: 10.1046/j.1471-4159.1997.68010162.x. J Neurochem. 1997. PMID: 8978722
-
Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.J Neurosci. 1992 Sep;12(9):3380-91. doi: 10.1523/JNEUROSCI.12-09-03380.1992. J Neurosci. 1992. PMID: 1527584 Free PMC article.
-
Release of cholecystokinin in the central nervous system.Neurochem Int. 1993 Jun;22(6):519-27. doi: 10.1016/0197-0186(93)90025-z. Neurochem Int. 1993. PMID: 8513278 Review.
-
Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors.Neurosci Biobehav Rev. 1994 Summer;18(2):207-14. doi: 10.1016/0149-7634(94)90025-6. Neurosci Biobehav Rev. 1994. PMID: 7914685 Review.
Cited by
-
Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.Psychopharmacology (Berl). 1996 Jan;123(2):131-43. doi: 10.1007/BF02246170. Psychopharmacology (Berl). 1996. PMID: 8741936
-
Cholecystokinin neurotransmission in the central nervous system: Insights into its role in health and disease.Biofactors. 2024 Nov-Dec;50(6):1060-1075. doi: 10.1002/biof.2081. Epub 2024 May 22. Biofactors. 2024. PMID: 38777339 Free PMC article. Review.
-
A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.CNS Neurosci Ther. 2019 Jan;25(1):136-146. doi: 10.1111/cns.12994. Epub 2018 Jun 20. CNS Neurosci Ther. 2019. PMID: 29923314 Free PMC article. Clinical Trial.
-
Acute effect of cholecystokinin on short-term synaptic plasticity in the rat hippocampus.Res Pharm Sci. 2014 Sep-Oct;9(5):331-6. Res Pharm Sci. 2014. PMID: 25657805 Free PMC article.
-
Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.J Physiol. 2004 Feb 15;555(Pt 1):71-84. doi: 10.1113/jphysiol.2003.056739. Epub 2003 Dec 12. J Physiol. 2004. PMID: 14673185 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources